[{"address1": "4400 Route 9 South", "address2": "Suite 1000", "city": "Freehold", "state": "NJ", "zip": "07728", "country": "United States", "phone": "877 265 8266", "website": "https://www.chromocell.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Mr. Francis  Knuettel II, M.B.A.", "age": 57, "title": "President, CEO, CFO, Treasurer, Secretary & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 107500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric  Lang M.D.", "age": 61, "title": "Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 264993, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.6601, "open": 0.68, "dayLow": 0.63, "dayHigh": 0.66, "regularMarketPreviousClose": 0.6601, "regularMarketOpen": 0.68, "regularMarketDayLow": 0.63, "regularMarketDayHigh": 0.66, "forwardPE": -0.57272726, "volume": 30289, "regularMarketVolume": 30289, "averageVolume": 148688, "averageVolume10days": 136610, "averageDailyVolume10Day": 136610, "bid": 0.605, "ask": 0.6544, "bidSize": 1100, "askSize": 3100, "marketCap": 3797646, "fiftyTwoWeekLow": 0.45, "fiftyTwoWeekHigh": 6.0, "fiftyDayAverage": 0.65474, "twoHundredDayAverage": 1.214355, "currency": "USD", "enterpriseValue": 2883994, "floatShares": 1325765, "sharesOutstanding": 6028010, "sharesShort": 58233, "sharesShortPriorMonth": 31672, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0101, "heldPercentInsiders": 0.80757004, "heldPercentInstitutions": 0.07071, "shortRatio": 0.26, "shortPercentOfFloat": 0.013300001, "impliedSharesOutstanding": 6028010, "bookValue": -1.646, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -9794834, "trailingEps": -1.81, "forwardEps": -1.1, "52WeekChange": -0.8625, "SandP52WeekChange": 0.2729931, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "CHRO", "underlyingSymbol": "CHRO", "shortName": "Channel Therapeutics Corporatio", "longName": "Channel Therapeutics Corporation", "firstTradeDateEpochUtc": 1708093800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "6f1c1782-f7b5-3f67-a9fa-2d3ca7aa4092", "messageBoardId": "finmb_1803540075", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.63, "targetHighPrice": 8.5, "targetLowPrice": 8.5, "targetMeanPrice": 8.5, "targetMedianPrice": 8.5, "recommendationKey": "none", "numberOfAnalystOpinions": 1, "totalCash": 2405098, "totalCashPerShare": 0.417, "totalDebt": 1587284, "quickRatio": 0.863, "currentRatio": 0.934, "returnOnAssets": -4.12802, "freeCashflow": -6493229, "operatingCashflow": -5558350, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-28"}]